Evidence map›Paper›PMID 36634844›Full record

ArticleThe ocular surface2023

Can Janus kinase inhibition improve ocular graft versus host disease?

Seema Sajjan, Ellis Tibbs, Megan Utz, Aaron P Rapoport, Jean Yared, Saurabh Dahiya, Xuefang Cao, Nancy Hardy, Sarah B Sunshine

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The ocular surface, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Seema SajjanDepartment of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Ellis TibbsMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Megan UtzDepartment of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Aaron P RapoportMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Jean YaredMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Saurabh DahiyaMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Xuefang CaoMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Nancy HardyMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Sarah B SunshineDepartment of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: SSunshine@som.umaryland.edu.

Funding

QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Beta-2 adrenergic signaling in immune homeostasis and reconstitutionR01HL159973 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI CAO, XUEFANG · 2022 to 2025
$3.0M
CD27/CD70 mediated negative regulation of inflammatory T cell responsesR01HL135325 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI CAO, XUEFANG · 2018 to 2021
$2.3M
Targeting Granzyme B to Separate GVH from GVL ResponsesR01CA184728 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI CAO, XUEFANG · 2015 to 2019
$1.9M
Targeting Beta-Adrenergic Signaling to Control GVH and GVL ResponsesR21CA202358 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI CAO, XUEFANG · 2016 to 2017
$435k
NCATS NIH HHS UL1 TR003098NCI NIH HHS R01 CA184728NCI NIH HHS R21 CA202358NHLBI NIH HHS R01 HL135325NHLBI NIH HHS R01 HL159973NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansJanus KinasesJanus KinasesJAK inhibitionOcular graft versus host diseaseOcular surface disease

Identifiers

PMID36634844
PMCPMC10683453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.